Results 61 to 70 of about 16,179 (202)
Frontrunner in Translation: Progressive Supranuclear Palsy
Frontiers in Neurology, 2019 Progressive supranuclear palsy (PSP) is a four-repeat tau proteinopathy. Abnormal tau deposition is not unique for PSP and is the basic pathologic finding in some other neurodegenerative disorders such as Alzheimer's disease (AD), age-related tauopathy ...
Ali Shoeibi, Nahid Olfati, Irene Litvan
doaj +1 more source
FXTAS and the Spectrum of FMR1 Premutation‐Associated Phenotypes in Latin America: A Scoping Review
Movement Disorders Clinical Practice, EarlyView.Abstract Background Fragile X–associated tremor/ataxia syndrome (FXTAS) is a late‐onset neurodegenerative disorder caused by FMR1 premutation expansions (55–200 CGG repeats). Although well described in populations of predominantly European ancestry, FXTAS remains poorly characterized in Latin America due to limited awareness, restricted access to ...
Amy Schmidmajer +6 more
wiley +1 more source
Diagnostic challenges in multiple system atrophy
Neuropsychiatric Disease and Treatment, 2018 Diana Obelieniene,1 Sandra Bauzaite,1 Ilona Kulakiene,2 Evaldas Keleras,2 Indre Eitmonaite,3 Daiva Rastenyte1 1Department of Neurology, 2Department of Radiology, 3Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania Abstract ...
Obelieniene D +5 more
doaj
Progressive supranuclear palsy and pawpaw
Neurology Clinical Practice, 2020 Consider consumption of annonacin-containing plant products, including pawpaw, as a possible environmental risk factor for atypical parkinsonism.
Bonnie Kaas +2 more
openaire +3 more sources
Multireceptor fingerprints in progressive supranuclear palsy
Alzheimer’s Research & Therapy, 2017 Background Progressive supranuclear palsy (PSP) with a frontal presentation, characterized by cognitive deficits and behavioral changes, has been recognized as an early clinical picture, distinct from the classical so-called Richardson and parkinsonism ...
Wang Zheng Chiu +7 more
doaj +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Continuous subcutaneous apomorphine infusion (CSAI) is effective in Parkinson's disease but has not been evaluated in multiple system atrophy (MSA). Objective To assess the 6‐month efficacy and tolerability of CSAI in MSA patients. Methods French multicenter retrospective registry‐based analysis of CSAI use in MSA.
Simon Lamy +16 more
wiley +1 more source
Simultaneous mixed phenotype and neuroimaging of progressive supranuclear palsy, progressive ataxia and palatal tremor: two different faces of tauopathies. [PDF]
Arq Neuropsiquiatr, 2022 Freitas LF +4 more
europepmc +1 more source
Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism
Movement Disorders Clinical Practice, EarlyView.Abstract Background Fracture risk is increased in Parkinson's yet this risk is often not addressed. Objectives Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Katie C. Naylor +2 more
wiley +1 more source
Annals of Indian Academy of Neurology, 2014 Aims: In progressive supranuclear palsy (PSP) tissue damage occurs in specific cortical and subcortical regions. Voxel based analysis using T1-weighted images depict quantitative gray matter (GM) atrophy changes.
Mangalore Sandhya +4 more
doaj +1 more source
Enteral Nutrition in Idiopathic Parkinson's Disease and Atypical Parkinsonism: A Systematic Review
Movement Disorders Clinical Practice, EarlyView.Abstract Background Dysphagia and malnutrition are common in advanced Parkinson's disease and atypical parkinsonism. There is a lack of evidence to guide the use of enteral nutrition in these situations, including whether it improves survival or reduces aspiration pneumonia.
Bradley Lonergan +3 more
wiley +1 more source